Abbott Laboratories $ABT Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. lowered its holdings in Abbott Laboratories (NYSE:ABT) by 2.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 509,767 shares of the healthcare product maker’s stock after selling 13,747 shares during the period. Brown Advisory Inc.’s holdings in Abbott Laboratories were worth $63,869,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $27,000. Intesa Sanpaolo Wealth Management purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $29,000. Prudent Man Investment Management Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $33,000. Finally, Leonteq Securities AG purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by company insiders.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $87.89 on Monday. The stock has a market capitalization of $153.08 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.47 and a beta of 0.63. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm’s 50-day moving average is $91.46 and its two-hundred day moving average is $107.84.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period last year, the company earned $1.09 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.9%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Analyst Ratings Changes

Several research firms recently commented on ABT. Weiss Ratings downgraded shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. Oppenheimer cut their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Argus lowered their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. BofA lowered their target price on Abbott Laboratories from $120.00 to $102.00 in a report on Friday. Finally, Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.38.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.